To the Editor Goffin et al1 provide model-based estimates on the cost-effectiveness of lung cancer screening in Canada. However, their analyses warrant additional clarification.
The authors state that they use general mortality rates. However, mortality differs substantially across different smoking behaviors.2 Therefore, the authors do not appropriately estimate the life-years and quality-adjusted life-years (QALYs) gained by screening.
Kevin ten Haaf, Harry J. de Koning. Clarifying Assumptions and Outcomes in Cost-effectiveness Analyses. JAMA Oncol. 2016;2(2):277–278. doi:10.1001/jamaoncol.2015.4457